Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

German Real-World Evidence Study on the Effectiveness of Foslevodopa/Foscarbidopa at Initial Stages of Advanced Parkinson's Disease: Motor Symptoms, Quality of Life, Psychosocial Functioning and Work Ability

NCT06916507 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06916507
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06916507 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
German Real-World Evidence Study on the Effectiveness of Foslevodopa/Foscarbidopa at Initial Stages of Advanced Parkinson's Disease: Motor Symptoms, Quality of Life, Psychosocial Functioning and Work Ability
Lead sponsor
AbbVie
Phase
Observational
Overall status
Recruiting
Start date
May 5, 2025
Completion date
June 30, 2028
Enrollment
125 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease